Dr. Ibrahim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
245 Terracina Blvd
Ste 206
Redlands, CA 92373Phone+1 909-793-4336Fax+1 909-793-3325- Is this information wrong?
Summary
- Dr. Emad Ibrahim is an oncologist in Redlands, CA and is affiliated with multiple hospitals in the area, including Loma Linda University Medical Center and Redlands Community Hospital. He received his medical degree from University of Alexandria Faculty of Medicine and has been in practice 30 years. He also speaks multiple languages, including Arabic. He specializes in hematology and medical oncology and is experienced in immune thrombocytopenic purpura, myeloproliferative disorders, Hodgkin's and non Hodgkin's lymphoma, multiple myeloma, lung, breast, prostate and colon cancer. He has several publications and over 250 citing. He is a full clinical professor at University of California School of Medicine and associate Professor at Loma Linda University. He is the director of Redlands Community Hospital Cancer program and runs an active clinical trials program at his practice.
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 1994 - 1997
- University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 1991 - 1994
- University of Alexandria Faculty of MedicineClass of 1988
Certifications & Licensure
- CA State Medical License 1992 - 2026
- WA State Medical License 1993 - 1999
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2023 Jun 30
Roles: Contact
Publications & Presentations
PubMed
- 9 citationsAn open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.Jeffrey L. Vacirca, Arlene Chan, Klára Mezei, Clarence S. Adoo, Zsuzsanna Pápai, Kimberly McGregor, Meena Okera, Zsolt Horváth, László Landherr, Jerzy Hanslik, Steven ...> ;Cancer Medicine. 2018 May 1
- 364 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3..., , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Oncology. 2017 Dec 1
- 24 citationsLow serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.James Wang, Kyle Udd, Aleksandra Vidisheva, Regina A. Swift, Tanya M. Spektor, Eric Bravin, Emad Ibrahim, Jonathan Treisman, Mohammed Masri, James R. Berenson> ;Supportive Care in Cancer. 2016 Feb 23
Professional Memberships
- Member
- Member
- Member
Other Languages
- Arabic
Hospital Affiliations
- Loma Linda University Medical CenterLoma Linda, California
- Redlands Community HospitalRedlands, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: